Synergistic Mn‐MOF Activation of Pistol Ribozymes for Cancer Immunotherapy
Open Access
- 10 February 2026
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (20) , e17912
Abstract
Checkpoint blockade therapies targeting PD‐L1 have revolutionized cancer immunotherapy, yet their efficacy is constrained by systemic immune toxicity and inadequate immune infiltration in certain tumor types. Here, we introduce a synergistic gene‐silencing nanosystem based on a target‐selective Pistol ribozyme (PS473) encapsulated within a manganese‐based, pH‐responsive metal–organic framework (NKMOF‐101‐[Mn]). The engineered PS473 exhibited high cleavage efficiency toward GU‐rich PD‐L1 mRNA motifs and was further activated by Mn 2 + cofactors. NKMOF‐101‐[Mn] not only protects the ribozyme from nuclease degradation but also enables localized Mn 2 + release to increase catalytic activity and innate immune signaling under the acidic tumor microenvironment. In vitro, PS473@NKMOF‐101‐[Mn] markedly suppressed PD‐L1 expression and promoted macrophage activation. In the B16F10 melanoma model, this system achieved over 90% tumor inhibition, enhanced immune cell infiltration and activation, and exhibited minimal systemic toxicity. Transcriptomic profiling further revealed the upregulation of immune‐related pathways, supporting a synergistic mechanism of gene silencing and immune activation. Overall, this study established a ribozyme‐directed immunotherapeutic platform with strong potential for precision cancer therapy via checkpoint modulation and immune reprogramming.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFA0913800)
- National Natural Science Foundation of China (22371136)
- National Natural Science Foundation of China (21877065)
- National Natural Science Foundation of China (82111530210)
- National Natural Science Foundation of China (32360709)
- Fundamental Research Funds for the Central Universities (035‐63191735)
- Fundamental Research Funds for the Central Universities (035–63221328)
This publication has 38 references indexed in Scilit:
- Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockadeAdvanced Drug Delivery Reviews, 2024
- Immunologic tumor microenvironment modulators for turning cold tumors hotCancer Communications, 2024
- Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatmentCoordination Chemistry Reviews, 2023
- MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapyCancer Letters, 2022
- Crucial Roles of Two Hydrated Mg2+ Ions in Reaction Catalysis of the Pistol RibozymeAngewandte Chemie International Edition, 2019
- Mechanisms Controlling PD-L1 Expression in CancerMolecular Cell, 2019
- Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA VirusesImmunity, 2018
- Structure-based mechanistic insights into catalysis by small self-cleaving ribozymesCurrent Opinion in Chemical Biology, 2017
- Atom‐Specific Mutagenesis Reveals Structural and Catalytic Roles for an Active‐Site Adenosine and Hydrated Mg2+ in Pistol RibozymesAngewandte Chemie International Edition, 2017
- Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell KillingAdvanced Healthcare Materials, 2015